Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Multiple Sclerosis

Free Subscription Articles published in J Neuroimmunol Retrieve available abstracts of 119 articles: HTML format

Single Articles

April 2024
1. LI S, Sun D, Wang R, Du Q, et al
   Causal association between multiple sclerosis and severe COVID-19: A bidirectional Mendelian randomization study.
   J Neuroimmunol. 2024;391:578352.
   PubMed    
   
   
   
2. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
   Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
   J Neuroimmunol. 2024;390:578347.
   PubMed     Abstract available
   
   
   
3. MUNZ C
   Altered EBV specific immune control in multiple sclerosis.
   J Neuroimmunol. 2024;390:578343.
   PubMed     Abstract available
   
   
   March 2024
4. HAHAM N, Zveik O, Rechtman A, Brill L, et al
   Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
   J Neuroimmunol. 2024;388:578289.
   PubMed     Abstract available
   
   
   
5. CHANG EH, Hardy TA
   Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
   J Neuroimmunol. 2024;389:578330.
   PubMed     Abstract available
   
   
   
6. FOGEL A, Olcer M, Goel A, Feng X, et al
   Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
   J Neuroimmunol. 2024;389:578328.
   PubMed     Abstract available
   
   
   February 2024
7. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
   Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
   J Neuroimmunol. 2024;390:578315.
   PubMed     Abstract available
   
   
   
8. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
   Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
   J Neuroimmunol. 2024;387:578286.
   PubMed     Abstract available
   
   
   
9. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
   EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
   J Neuroimmunol. 2024;389:578314.
   PubMed     Abstract available
   
   
   
10. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
    Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
    J Neuroimmunol. 2024;389:578313.
    PubMed     Abstract available
    
    
    
11. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
    Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2024;388:578299.
    PubMed     Abstract available
    
    
    January 2024
12. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
    Dysregulated autotaxin expression by T cells in multiple sclerosis.
    J Neuroimmunol. 2024;387:578282.
    PubMed     Abstract available
    
    
    
13. FUJIMORI J, Nakashima I
    Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    J Neuroimmunol. 2024;387:578280.
    PubMed     Abstract available
    
    
    December 2023
14. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
    Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    J Neuroimmunol. 2023;387:578268.
    PubMed     Abstract available
    
    
    
15. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
    Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    J Neuroimmunol. 2023;387:578270.
    PubMed     Abstract available
    
    
    
16. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    PubMed     Abstract available
    
    
    November 2023
17. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
    Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
    J Neuroimmunol. 2023;385:578240.
    PubMed     Abstract available
    
    
    October 2023
18. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    PubMed     Abstract available
    
    
    September 2023
19. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
    Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
    J Neuroimmunol. 2023;383:578202.
    PubMed     Abstract available
    
    
    
20. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
    Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
    J Neuroimmunol. 2023;384:578200.
    PubMed     Abstract available
    
    
    
21. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
    Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    J Neuroimmunol. 2023;383:578199.
    PubMed     Abstract available
    
    
    
22. PERDAENS O, van Pesch V
    MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
    J Neuroimmunol. 2023;386:578196.
    PubMed     Abstract available
    
    
    August 2023
23. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
    Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2023;383:578178.
    PubMed     Abstract available
    
    
    
24. BALAZS I, Horvath A, Heschl B, Khalil M, et al
    Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases.
    J Neuroimmunol. 2023;381:578136.
    PubMed     Abstract available
    
    
    
25. SOTTINI A, Quaresima V, Barbaro M, Moiola L, et al
    Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
    J Neuroimmunol. 2023;382:578170.
    PubMed     Abstract available
    
    
    
26. BRUNE-INGEBRETSEN S, Hogestol EA, de Rosbo NK, Berg-Hansen P, et al
    Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis.
    J Neuroimmunol. 2023;382:578175.
    PubMed     Abstract available
    
    
    July 2023
27. ADAMEC I, Brecl Jakob G, Rajda C, Drulovic J, et al
    Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    J Neuroimmunol. 2023;382:578164.
    PubMed     Abstract available
    
    
    
28. PRIEGO M, Noriega L, Kalinin S, Hoffman LM, et al
    Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2023;382:578152.
    PubMed     Abstract available
    
    
    June 2023
29. ELKJAER ML, Lohse RM, Burton M, Mendoza JP, et al
    Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
    J Neuroimmunol. 2023;381:578145.
    PubMed     Abstract available
    
    
    
30. BLASK C, Schulze J, Rumpel S, Susse M, et al
    Modulation of cytokine release from peripheral blood mononuclear cells from multiple sclerosis patients by coenzyme A and soraphen A.
    J Neuroimmunol. 2023;381:578135.
    PubMed     Abstract available
    
    
    
31. SI W, Ni Y, Jiang Q, Tan L, et al
    Nanopore sequencing identifies differentially methylated genes in the central nervous system in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2023;381:578134.
    PubMed     Abstract available
    
    
    
32. CARIA P, Pilotto S, D'Alterio MN, Fronza M, et al
    Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.
    J Neuroimmunol. 2023;381:578137.
    PubMed     Abstract available
    
    
    
33. MICHETTI L, Maffina F, Ravasio R, Barcella V, et al
    Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases.
    J Neuroimmunol. 2023;379:578091.
    PubMed     Abstract available
    
    
    
34. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Cerebrospinal fluid soluble CD27 is associated with CD8(+) T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2023;381:578128.
    PubMed     Abstract available
    
    
    May 2023
35. MARSTERS C, Nathoo N, Amatto L, Wong R, et al
    Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
    J Neuroimmunol. 2023;380:578110.
    PubMed     Abstract available
    
    
    
36. GE A, Sun Y, Kiker T, Zhou Y, et al
    A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis.
    J Neuroimmunol. 2023;379:578105.
    PubMed     Abstract available
    
    
    
37. MANZANO GS, Rice DR, Zurawski J, Jalkh Y, et al
    Familial Mediterranean Fever and multiple sclerosis treated with ocrelizumab: Case report.
    J Neuroimmunol. 2023;379:578099.
    PubMed     Abstract available
    
    
    
38. XUE Y, Zhang L, Guo R, Shao X, et al
    miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3.
    J Neuroimmunol. 2023;379:578100.
    PubMed     Abstract available
    
    
    April 2023
39. MULLER-MINY L, Heming M, Lautwein T, Ruck T, et al
    Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2023;378:578088.
    PubMed     Abstract available
    
    
    
40. VACARAS V, Muresanu DF, Buzoianu AD, Nistor C, et al
    The role of multiple sclerosis therapies on the dynamic of human gut microbiota.
    J Neuroimmunol. 2023;378:578087.
    PubMed     Abstract available
    
    
    March 2023
41. ABBADESSA G, Miele G, Cavalla P, Valentino P, et al
    Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.
    J Neuroimmunol. 2023;378:578072.
    PubMed     Abstract available
    
    
    
42. FERREIRA F, Ferreira D, Guimaraes J, Soares-Dos-Reis R, et al
    Recurrent encephalopathy associated with pegylated beta-interferon treatment.
    J Neuroimmunol. 2023;376:578037.
    PubMed     Abstract available
    
    
    
43. PALACIO PL, Pleet ML, Reategui E, Magana SM, et al
    Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.
    J Neuroimmunol. 2023;377:578064.
    PubMed     Abstract available
    
    
    January 2023
44. SERAFINI B, Rosicarelli B, Veroni C, Aloisi F, et al
    Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells.
    J Neuroimmunol. 2023;376:578036.
    PubMed     Abstract available
    
    
    December 2022
45. CURRAN C, Vaitaitis G, Waid D, Volmer T, et al
    Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).
    J Neuroimmunol. 2022;374:578008.
    PubMed     Abstract available
    
    
    November 2022
46. SHU Y, Ma X, Chen C, Wang Y, et al
    Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.
    J Neuroimmunol. 2022;372:577937.
    PubMed     Abstract available
    
    
    October 2022
47. LI X, Chu Y, Ma R, Dou M, et al
    Ferroptosis as a mechanism of oligodendrocyte loss and demyelination in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;373:577995.
    PubMed     Abstract available
    
    
    
48. CUTELLE C, Balducci C, Cereda D, Fusco ML, et al
    K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis.
    J Neuroimmunol. 2022;373:577992.
    PubMed     Abstract available
    
    
    
49. DE SOUZA TIEPPO EM, da Silva TFF, de Araujo RS, Silva GD, et al
    Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report.
    J Neuroimmunol. 2022;373:577991.
    PubMed     Abstract available
    
    
    
50. FEIZI P, Sharma K, Pasham SR, Nirwan L, et al
    Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review.
    J Neuroimmunol. 2022;371:577939.
    PubMed     Abstract available
    
    
    September 2022
51. FARAJI J, Gustafson C, Bettenson D, Negoro H, et al
    Bladder dysfunction in experimental autoimmune encephalomyelitis reflects clinical severity: A pilot study.
    J Neuroimmunol. 2022;372:577973.
    PubMed     Abstract available
    
    
    
52. MAGALASHVILI D, Mandel M, Dreyer-Alster S, Didikin M, et al
    Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
    J Neuroimmunol. 2022;372:577966.
    PubMed     Abstract available
    
    
    July 2022
53. ALOISI F, Cross AH
    MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    J Neuroimmunol. 2022;371:577935.
    PubMed     Abstract available
    
    
    
54. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
    J Neuroimmunol. 2022;371:577936.
    PubMed     Abstract available
    
    
    
55. DAS NEVES SP, Serre-Miranda C, Sousa JC, Costa PS, et al
    Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system.
    J Neuroimmunol. 2022;368:577872.
    PubMed     Abstract available
    
    
    
56. VAN DER WEELE L, Pollastro S, van Schaik BDC, van Kampen AHC, et al
    Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif) using B cell receptor repertoire analysis.
    J Neuroimmunol. 2022;370:577932.
    PubMed     Abstract available
    
    
    
57. KASHEKE GDS, Holman SP, Robertson GS
    Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;370:577926.
    PubMed     Abstract available
    
    
    June 2022
58. CHAN F, Riminton DS, Ramanathan S, Reddel SW, et al
    Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases.
    J Neuroimmunol. 2022;369:577904.
    PubMed     Abstract available
    
    
    April 2022
59. KYLLESBECH C, Trier N, Slibinskas R, Ciplys E, et al
    Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
    J Neuroimmunol. 2022;367:577868.
    PubMed     Abstract available
    
    
    March 2022
60. TOTTENHAM I, Koch M, Camara-Lemarroy C
    Serum HGF and APN2 are associated with disability worsening in SPMS.
    J Neuroimmunol. 2022;364:577803.
    PubMed     Abstract available
    
    
    
61. SALARI AA, Jand Y, Ghazi-Khansari M
    Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;366:577840.
    PubMed     Abstract available
    
    
    January 2022
62. KALININ S, Boullerne AI, Feinstein DL
    Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2022;364:577810.
    PubMed     Abstract available
    
    
    
63. YE F, Dai Y, Wang T, Liang J, et al
    Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2022;364:577809.
    PubMed     Abstract available
    
    
    
64. BRORSON IS, Eriksson AM, Hogestol E, Leikfoss IS, et al
    Global DNA methylation changes in treated and untreated MS patients measured over time.
    J Neuroimmunol. 2022;364:577808.
    PubMed     Abstract available
    
    
    December 2021
65. TALBOT J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, et al
    Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    J Neuroimmunol. 2021;361:577756.
    PubMed     Abstract available
    
    
    
66. KESHVARI MK, van Someren F, Sheikh S, Galea I, et al
    Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
    J Neuroimmunol. 2021;361:577729.
    PubMed     Abstract available
    
    
    
67. ADAMEC I, Rogic D, Penz MG, Braun C, et al
    Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    J Neuroimmunol. 2021;362:577788.
    PubMed     Abstract available
    
    
    
68. TOLJAN K, Amin M, Kunchok A, Ontaneda D, et al
    New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
    J Neuroimmunol. 2021;362:577785.
    PubMed     Abstract available
    
    
    November 2021
69. CARAVAGNA C
    Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
    J Neuroimmunol. 2021;362:577780.
    PubMed    
    
    
    
70. HASSANSHAHI G, Noroozi Karimabad M, Jebali A
    The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
    J Neuroimmunol. 2021;362:577768.
    PubMed     Abstract available
    
    
    
71. FREEDMAN MS, Wojcik J, Holmberg KH, Fluck M, et al
    Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
    J Neuroimmunol. 2021;360:577715.
    PubMed     Abstract available
    
    
    
72. PACHE F, Ringelstein M, Aktas O, Kleiter I, et al
    C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    J Neuroimmunol. 2021;360:577699.
    PubMed     Abstract available
    
    
    
73. MASCIA E, Clarelli F, Zauli A, Guaschino C, et al
    Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.
    J Neuroimmunol. 2021;362:577760.
    PubMed     Abstract available
    
    
    October 2021
74. VAKRAKOU AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, et al
    IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;361:577759.
    PubMed     Abstract available
    
    
    
75. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    PubMed     Abstract available
    
    
    
76. ACHIRON A, Mandel M, Dreyer-Alster S, Harari G, et al
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
    J Neuroimmunol. 2021;361:577746.
    PubMed     Abstract available
    
    
    September 2021
77. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available
    
    
    August 2021
78. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available
    
    
    
79. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available
    
    
    
80. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available
    
    
    
81. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available
    
    
    
82. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available
    
    
    July 2021
83. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available
    
    
    
84. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available
    
    
    
85. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available
    
    
    
86. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available
    
    
    
87. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available
    
    
    June 2021
88. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available
    
    
    
89. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available
    
    
    
90. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available
    
    
    
91. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available
    
    
    May 2021
92. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available
    
    
    
93. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available
    
    
    
94. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available
    
    
    April 2021
95. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    PubMed    
    
    
    
96. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available
    
    
    
97. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available
    
    
    
98. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available
    
    
    March 2021
99. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available
    
    
    
100. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
     Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
     J Neuroimmunol. 2021;354:577541.
     PubMed     Abstract available
     
     
     February 2021
101. XIANG W, Xie C, Guan Y
     The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
     J Neuroimmunol. 2021;354:577520.
     PubMed     Abstract available
     
     
     
102. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
     Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
     J Neuroimmunol. 2021;353:577525.
     PubMed     Abstract available
     
     
     
103. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
     Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
     J Neuroimmunol. 2021;353:577500.
     PubMed     Abstract available
     
     
     
104. LI Q, Liu Y, Zeng Y
     Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
     J Neuroimmunol. 2021;353:577516.
     PubMed    
     
     
     January 2021
105. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
     An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
     J Neuroimmunol. 2021;353:577507.
     PubMed     Abstract available
     
     
     
106. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
     NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
     J Neuroimmunol. 2021;353:577499.
     PubMed     Abstract available
     
     
     
107. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
     Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
     J Neuroimmunol. 2021;353:577497.
     PubMed     Abstract available
     
     
     
108. NIU Y, Li Y
     The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
     J Neuroimmunol. 2021;352:577465.
     PubMed    
     
     
     
109. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
     Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
     J Neuroimmunol. 2021;352:577473.
     PubMed     Abstract available
     
     
     December 2020
110. STASCHEIT F, Li L, Mai K, Baum K, et al
     Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
     J Neuroimmunol. 2020;351:577469.
     PubMed     Abstract available
     
     
     
111. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
     Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
     J Neuroimmunol. 2020;351:577466.
     PubMed     Abstract available
     
     
     
112. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
     A bibliometric evaluation of the top 100 cited natalizumab articles.
     J Neuroimmunol. 2020;349:577379.
     PubMed     Abstract available
     
     
     November 2020
113. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
     Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
     J Neuroimmunol. 2020;350:577432.
     PubMed     Abstract available
     
     
     
114. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
     Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
     J Neuroimmunol. 2020;350:577433.
     PubMed     Abstract available
     
     
     
115. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
     Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
     J Neuroimmunol. 2020;350:577435.
     PubMed     Abstract available
     
     
     October 2020
116. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
     Modelling multiple sclerosis using induced pluripotent stem cells.
     J Neuroimmunol. 2020;349:577425.
     PubMed     Abstract available
     
     
     September 2020
117. NEKRASOVA I, Shirshev S
     Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
     J Neuroimmunol. 2020;349:577421.
     PubMed     Abstract available
     
     
     
118. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
     Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
     J Neuroimmunol. 2020;349:577392.
     PubMed     Abstract available
     
     
     June 2020
119. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
     Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
     J Neuroimmunol. 2020;343:577230.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.